



Cohance Lifesciences Appoints Yann D'Herve as CEO of CDMO Business, Effective August 1, 2025.

Hyderabad/Mumbai, July 28, 2025

Cohance Lifesciences Ltd. ("Cohance" or "the Company"), a leading integrated Contract Development and Manufacturing Organization (CDMO), today announced the appointment of Mr. Yann D'Herve as Chief Executive Officer of the company's CDMO business. The business operates as a fully integrated, innovation-led platform serving global pharmaceutical companies, including capabilities in small molecule APIs, Antibody Drug Conjugates (ADCs) and Nucleic Acid Chemistry .

Effective August 1, 2025, D'Herve's appointment brings a strong track record of senior-level leadership to Cohance. He has a rich and diverse background spanning multiple business functions and geographies. His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors.

Most recently, D'Herve served as Senior Vice President and General Manager of Evonik's Healthcare division, where he was responsible for 2,600 employees across nine manufacturing sites, with full P&L responsibility, including for the company's CDMO business. Prior to that, he held several senior roles at Evonik including as Vice President of Sales and Services, and divisional leadership assignments. He began his career in manufacturing, gaining hands-on experience in production and operations. Mr. D'Herve holds an MBA from Université de Picardie Jules Verne in Amiens, and a master's in chemistry from CPE, Lyon, France.

On the appointment of Mr. Yann D'Herve, **Mr. Vivek Sharma, Executive Chairman of Cohance Lifesciences Ltd.**, commented, "We are delighted to welcome Yann to

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad
Knowledge City, TSILC, Raidurg, Hyderabad - 500081, Telangana, India.
Tel: +91 40 2354 9414 / 3311

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road,
Chakala, Andheri East, Chakala MIDC, Mumbai - 400093, Maharashtra, India.
Tel: +91 22 6153 9999

CIN: L24299MH2018PLC422236 | Website: www.suvenpharm.com | Company Email: info@suvenpharm.com

Cohance. His deep experience in leading multifaceted global pharmaceutical services businesses will be of tremendous benefit in accelerating the growth of our CDMO platform.”

Mr. Yann D’Herve, shared:

“I am excited to join a growing CDMO with differentiated technologies such as ADCs and oligonucleotides and a strong global asset base. I look forward to working with the Cohance team to support the development and manufacturing of life-saving drugs for our partners.”.

-ENDS-

For more information, please contact:

Cyndrella Carvalho, Head - Investor Relations,
Cohance Lifesciences Limited
Tel: 040 2354 3311
Email: cyndrella.carvalho@cohance.com

Gavin Desa / Rishab Barar
CDR India
Tel: +91 98206 37649/ +91 77770 35061
Email: gavin@cdr-india.com
rishab@cdr-india.com

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana, India.
Tel: +91 40 2354 9414 / 3311

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala MIDC, Mumbai - 400093, Maharashtra, India.
Tel: +91 22 6153 9999

CIN: L24299MH2018PLC422236 | Website: www.suvenpharm.com | Company Email: info@suvenpharm.com